Inexpensive compounding of low-dose naltrexone (LDN) with orange juice

Bronfenbrener, Roman

doi:10.1016/j.jaad.2019.03.067

Cited by 4 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low-dose naltrexone maintains stability and efficacy through 90 days when crushed into water. At the time of reporting, this solution cost about $15 for a three-month supply [18]. Strazzulla et al report a typical monthly cost of $35 [2].…”

Section: Discussionmentioning

confidence: 99%

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

Hamel¹,

Chen²,

O’Connell³

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundFrontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA and LPP. MethodsA single-center, uncontrolled open-label prospective study was performed, with 26 patients who took lowdose naltrexone for one year included in the per-protocol analysis. Both patient-reported (pruritus and burning/pain) and physician-assessed (erythema, scale, and scalp involvement) outcomes were analyzed. ResultsThere were decreases in erythema and scale for the overall longitudinal outcomes using linear mixed effects model analysis. However, only erythema had a significant decrease at 12 months compared with baseline. Mean erythema decreased by 0.93 at 12 months compared with baseline on a 0-3-point scale (p<0.0001, 95% mean CI [-1.32, -0.53]). There was no statistically significant difference comparing 12 months to baseline for the other outcomes including pruritus, burning/pain, and scalp involvement. Limitations include the possibility of spontaneous stabilization, concurrent medications, a small sample size with limited racial diversity, and mild subjective symptoms at baseline. ConclusionOur study supports further investigation of oral low-dose naltrexone as adjunctive therapy in the treatment of FFA and LPP if there is prominent erythema, and possibly scale.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

Hamel¹,

Chen²,

O’Connell³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…A trial of low-dose (3 mg) naltrexone daily was initiated, using compounding to a 1 mg/mL solution. 8 Clobetasol ointment under occlusion was continued.…”

Section: Case Descriptionmentioning

confidence: 99%